HIV was the crucible for the concept of expedited approval pathways, but drug development in the field has largely remained in a mature consolidation phase for the past decade. Indeed, the US FDA's recent approval of TaiMed Biologics Inc.'s Trogarzo (ibalizumab-uiyk) is notable not only as the first HIV approval to carry a breakthrough therapy designation (BTD), but also as the first new mechanism of action to reach the market for HIV therapy in 10 years.
FDA approved the CD4-directed post-attachment HIV-1 inhibitor Trogarzo on March 6, 2018 for treatment of heavily treatment-experienced adults whose multidrug...








